U.S. patent application number 15/132707 was filed with the patent office on 2017-01-26 for crystallization method and bioavailability.
The applicant listed for this patent is THAR PHARMACEUTICALS, INC.. Invention is credited to Miranda L. CHENEY, Mazen HANNA, Raymond K. HOUCK, Ning SHAN, David R. WEYNA.
Application Number | 20170022226 15/132707 |
Document ID | / |
Family ID | 43527595 |
Filed Date | 2017-01-26 |
United States Patent
Application |
20170022226 |
Kind Code |
A1 |
HANNA; Mazen ; et
al. |
January 26, 2017 |
CRYSTALLIZATION METHOD AND BIOAVAILABILITY
Abstract
Preparation, in-vitro and in vivo characterization of novel
forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic
acid, suitable for pharmaceutical compositions in drug delivery
systems for humans.
Inventors: |
HANNA; Mazen; (Lutz, FL)
; SHAN; Ning; (Tampa, FL) ; CHENEY; Miranda
L.; (Bishops Quay, IE) ; WEYNA; David R.;
(Lutz, FL) ; HOUCK; Raymond K.; (Oakmont,
PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THAR PHARMACEUTICALS, INC. |
Pittsburgh |
PA |
US |
|
|
Family ID: |
43527595 |
Appl. No.: |
15/132707 |
Filed: |
April 19, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13826691 |
Mar 14, 2013 |
9334296 |
|
|
15132707 |
|
|
|
|
12847568 |
Jul 30, 2010 |
8399023 |
|
|
13826691 |
|
|
|
|
61230222 |
Jul 31, 2009 |
|
|
|
61288036 |
Dec 18, 2009 |
|
|
|
61302110 |
Feb 6, 2010 |
|
|
|
61312879 |
Mar 11, 2010 |
|
|
|
61318503 |
Mar 29, 2010 |
|
|
|
61359544 |
Jun 29, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 37/04 20180101;
A61P 19/10 20180101; A61K 31/375 20130101; C07F 9/6506 20130101;
A61P 9/00 20180101; A61K 31/675 20130101; A61P 35/04 20180101; C07B
2200/13 20130101; A61P 35/00 20180101; A61P 3/14 20180101; A61P
19/08 20180101; A61P 7/00 20180101 |
International
Class: |
C07F 9/6506 20060101
C07F009/6506 |
Claims
1. A molecular complex comprising zoledronic acid and sodium.
2. A pharmaceutical composition comprising a molecular complex of
claim 1 and a pharmaceutically acceptable excipient.
3. A pharmaceutical composition according to claim 2, wherein the
composition is an oral dosage form.
4. A molecular complex of claim 1, wherein the molecular complex is
crystalline.
5. A molecular complex of claim 1 comprising zoledronic acid,
sodium zoledronate and water.
6. A molecular complex of claim 5, wherein the molecular complex is
crystalline.
7. A pharmaceutical composition comprising a molecular complex of
claim 4 and a pharmaceutically acceptable excipient.
8. A pharmaceutical composition according to claim 7, wherein the
composition is an oral dosage form.
9. A molecular complex of claim 5, wherein the sodium zoledronate
is monosodium zoledronate.
10. A pharmaceutical composition comprising a molecular complex of
claim 9 and a pharmaceutically acceptable excipient.
11. A molecular complex of claim 5, wherein the sodium zoledronate
is disodium zoledronate.
12. A pharmaceutical composition comprising a molecular complex of
claim 11 and a pharmaceutically acceptable excipient.
13. A method for the treatment of disease states associated with
osteoporosis, hypercalcemia, cancer induced bone metastasis,
Paget's disease or adjuvant or neoadjuvant cancer therapies
comprising the step of administering to a patient in need thereof a
therapeutically effective amount of the molecular complex according
to claim 1.
14. A method for the treatment of disease states associated with
osteoporosis, hypercalcemia, cancer induced bone metastasis,
Paget's disease or adjuvant or neoadjuvant cancer therapies
comprising the step of administering to a patient in need thereof a
therapeutically effective amount of the molecular complex according
to claim 5.
15. A method for the treatment of disease states associated with
osteoporosis, hypercalcemia, cancer induced bone metastasis,
Paget's disease or adjuvant or neoadjuvant cancer therapies
comprising the step of administering to a patient in need thereof a
therapeutically effective amount of the molecular complex according
to claim 9.
16. A method for the treatment of disease states associated with
osteoporosis, hypercalcemia, cancer induced bone metastasis,
Paget's disease or adjuvant or neoadjuvant cancer therapies
comprising the step of administering to a patient in need thereof a
therapeutically effective amount of the molecular complex according
to claim 11.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 13/826,691, filed on Mar. 14, 2013, now pending; which is a
continuation of U.S. application Ser. No. 12/847,568, filed Jul.
30, 2010, now U.S. Pat. No. 8,399,023; which claims priority to
U.S. application 61/230,222, filed Jul. 31, 2009; to U.S.
application 61/288,036, filed Dec. 18, 2009; to U.S. application
61/302,110, filed Feb. 6, 2010; to U.S. application 61/312,879,
filed Mar. 11, 2010; to U.S. application 61/318,503, filed Mar. 29,
2010; and to U.S. application 61/359,544, filed Jun. 29, 2010; each
of which is incorporated herein by reference.
FIELD OF THE INVENTION
[0002] This disclosure pertains to improvement of the aqueous
solubility and permeability of poorly permeable and sparingly water
soluble drug compounds through generating novel crystalline forms
of such drugs. The novel forms include but are not limited to
cocrystals, salts, hydrates, solvates, solvates of salts, and
mixtures thereof. Methods for the preparation and pharmaceutical
compositions suitable for drug delivery systems that include one or
more of these new forms are disclosed.
BACKGROUND OF THE INVENTION
[0003] Many Biopharmaceutic Classification System (BCS) class III
or IV drugs suffer from the lack of gastrointestinal (GI) tract
membrane permeability leading to poor oral bioavailability.
Different strategies have been implemented to improve the
permeability and subsequently the oral bioavailability of such
drugs. For example, the U.S. patent application 20060068010
describes a formulation method for improving the permeability of
drugs and subsequently increasing their bioavailability by
granulation of the physical solid mixture of the drug with one or
more amino acids, at least one inter-granular hydrophilic polymer,
and an additional immediate release excipient. Another application
WO 200602009 A1 disclosed the increase of the oral bioavailability
for poorly permeable drugs such as bisphosphonates; risedronate as
one of those drugs was mixed with a chelating agent such as
ethylenediaminetetraacetate (EDTA) and other excipients to make an
oral dosage form. Yet another application, WO 2007093226 A1,
describes a method for improving the bioavailability of ibandronate
by generating a physical mixture of the drug together with a
modified amino acid (acylation or sulphonation of the amino group
with phenyl or cyclohexyl) and other excipients. Another
application WO 2003007916 A1 reports a gastric retention system to
improve the bioavailability of a poorly permeable drug,
alendronate, which was orally formulated with vitamin D and
released an hour after the immediate release of vitamin D. WO
2006080780 discloses yet another method to improve the permeability
and bioavailability of alendronate, a poorly permeable
bisphosphonate, by mixing it with a biocompatible cationic polymer
(i.e. water soluble chitosan) with up to a 10:1 weight ratio of the
chitosan to the drug, while the resulting mixture can be formulated
into a solid or liquid oral dosage form. A further method of
improving permeability of drug materials was discussed in the U.S.
patent application 2007/014319 A1, where an oral dosage form was
formulated by a powder mixture of a bisphosphonic acid (e.g.
zoledronic acid) together with an inactive ingredient (either an
ester of a medium chain fatty acid or a lipophilic polyethylene
glycol ester). A similar approach was disclosed in the US
application 2007/0238707 A1 where a medium length fatty acid or its
derivative (6-20 carbon atom fatty acid chain) was physically mixed
with a poorly permeable drug (e.g. zoledronic acid) in a capsule
that was enterically coated.
[0004] Zoledronic acid, known as
(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, is
depicted by the following chemical structure:
##STR00001##
Zoledronic acid is a third generation bisphosphonate which far
exceeds the previous generations in terms of efficacy and is used
predominately for indications of osteoporosis, Paget's disease,
hypercalcemia, and inhibition of bone metastasis. It was originally
developed by Novartis and marketed as the monohydrate under the
brand names Zometa.RTM. and Reclast.RTM.. Zoledronic acid was first
approved in 2000 for the treatment of hypercalcemia in Canada. It
was later approved for use in the US for hypercalcemia in 2001, for
multiple myeloma and bone metastases from solid tumors in 2002, and
for osteoporosis and Paget's disease in 2007. Clinical trials have
also been conducted or are on-going exploring the use of zoledronic
acid in neoadjuvant or adjuvant cancer therapy, Coleman, et al.,
British J Cancer 2010; 102(7):1099-1105, Gnant, et al., New England
J Medicine. 2009, 360 (17):679-691 and Davies, et al. J Clinical
Oncology, 2010, 28(7s): Abstract 8021. Zoledronic acid is
administered as an intravenous (IV) dose of 4 mg over 15 minutes
for hypercalcemia of malignancy, multiple myeloma, and bone
metastases from solid tumors, while an IV dose of 5 mg over 15
minutes is used for osteoporosis and Paget's disease.
[0005] Zoledronic acid is sparingly soluble in water and 0.1 N HCl
solution but is freely soluble in 0.1 N NaOH. Zoledronic acid is
practically insoluble in various organic solvents.
[0006] Much effort has been taken to generate novel oral
formulations of zoledronic acid through crystallization and metal
salt formation to improve its aqueous solubility, permeability, and
subsequent oral bioavailability. A crystalline trihydrate was
disclosed in the U.S. Patent application 2006/0178439 A1 and world
patent application WO2007/032808. Seven hydrated forms, an
amorphous form, three monosodium salts, and eleven disodium salts
with varying degrees of hydration of zoledronic acid were also
disclosed in the patent application WO2005/005447 A2. Zoledronate
metal salts including Na.sup.+, Mg.sup.2+, Zn.sup.2+ were reported
in the journal of Drugs of the Future (Sorbera et al, 25(3), Drugs
of the Future, (2000)). Zoledronate, zoledronic, or zoledronic salt
represents the ionic form of zoledronic acid. Patent application
WO2008/064849 A1 from Novartis disclosed additional metal salts
including two Ca.sup.2+ salts, two Zn.sup.2+ salts, one Mg.sup.2+
salt, as well as a monohydrate, a trihydrate, an amorphous form,
and an anhydrous form.
[0007] According to the US Food and Drug Administration (FDA)
Summary Basis of Approval (SBA) for zoledronic acid, the poor oral
bioavailability (approximately 1%), is partially due to its poor
permeability in the GI tract. It was also noted that insoluble
metal complexes were formed in the upper intestines, most commonly
with calcium. Zoledronic acid has also been shown to cause severe
gastric and intestinal irritations.
[0008] All of the above attempts to improve the oral
bioavailability of zoledronic acid were either focused on improving
the aqueous solubility by generating novel solid forms, or by
mixing the drug with an inactive ingredient that has enhanced GI
tract permeability. The improvement of aqueous solubility failed to
improve the bioavailability of zoledronic acid, since the formation
of insoluble zoledronate calcium complexes is unlikely to be
prevented. On the other hand, powder mixtures of the poorly
permeable drug with inactive permeability enhancers improved the
bioavailability of the drug. This approach of mixing different
materials with different particle sizes and size distributions
could result in a poor blend/physical mixture uniformity.
Constituents of the mixture could also segregate during
transportation or with shaking and vibration. Additionally, the
powder blends require rigorous batch-to-batch consistency to ensure
the uniformity of the blend batches.
[0009] To the best of the inventors' knowledge, no attempt has been
made prior to this invention towards a deliberate molecular design
to create a molecular complex of the drug and additional
component(s) (coformer(s)) in a single crystalline structure. The
benefit of such design can lead to the elimination of all the batch
to batch blend uniformity and particle segregation problems that
powder blends often suffer from. In addition, this invention
simplifies the manufacturing of the solid dosage form (comprised of
drug and excipient) such that the final solid dosage form is, in
one embodiment, a powder of the molecular complex.
[0010] Additionally, the resulting molecular complexes possess very
different physicochemical properties compared to the parent drug,
coformer or their physical mixture. These properties include but
are not limited to melting point, thermal and electrical
conductivity, aqueous solubility, rate of dissolution and
permeability across the GI tract membrane. The permeability
improvement could result in the enhancement of the oral
bioavailability of the BCS class III and IV drugs. This is the
first time that the concept of a molecular complex by design was
employed to improve the permeability and subsequent bioavailability
of a poorly permeable drug such as zoledronic acid. The mechanisms
behind the permeability enhancement, however, are not fully
understood.
[0011] The upward trend in the use of oral drugs continues
especially in light of the goal to decrease the overall cost of
healthcare. Orally administered drugs are becoming more preferred
in various therapeutic areas including cancers. Clearly, there is
an opportunity to create oral dosage forms of IV drugs where oral
dosage forms do not yet exist due to their poor aqueous solubility
and/or poor permeability providing a clear clinical benefit for
patients. Given the fact that zoledronic acid is only approved for
IV administration, there is a need to develop an oral dosage form
of zoledronic acid. By using pharmaceutically acceptable and/or
approved coformers to hydrogen bond with zoledronic acid, novel
molecular complexes (e.g. cocrystals, salts, solvates, and mixtures
thereof) with improve solubility and/or permeability can be
created. These novel molecular complexes could be used in the
development of an oral dosage form for zoledronic acid.
SUMMARY OF THE INVENTION
[0012] The present disclosure is directed towards generating new
forms of zoledronic acid, which have the therapeutic efficacy of
zoledronic acid discussed above, with improved aqueous solubility,
rate of dissolution, and/or improved permeability and thus enhanced
bioavailability. One aspect of the present disclosure includes
novel molecular complexes of zoledronic acid that includes
cocrystals, salts, and solvates (e.g. hydrates and mixed solvates
as well as solvates of salts), and mixtures containing such
materials. In addition, the disclosure further includes methods for
the preparation of such complexes.
[0013] The disclosure further includes compositions of molecular
complexes of zoledronic acid suitable for incorporation in a
pharmaceutical dosage form. Specific molecular complexes pertaining
to the disclosure include, but are not limited to, complexes of
zoledronic acid with sodium, ammonium, ammonia, L-lysine,
DL-lysine, nicotinamide, adenine, and glycine. Obvious variants of
the disclosed zoledronic acid forms in the disclosure, including
those described by the drawings and examples, will be readily
apparent to the person of ordinary skill in the art having the
present disclosure and such variants are considered to be a part of
the current invention.
[0014] The disclosure also includes results of an in vivo study of
parent (pure) zoledronic acid and selected zoledronic acid
complexes prepared by the methods of the invention in rat and dog
models. The drug concentrations in the rat plasma and dog serum
samples along with the pharmacokinetic (PK) profiles are also
included.
[0015] The foregoing and other features and advantages of the
disclosed technology will become more apparent from the following
detailed description, which proceeds with reference to the
accompanying drawings. Such description is meant to be
illustrative, but not limiting, of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows PXRD diffractograms of: (A=zoledronic acid,
sodium zoledronic salt and water complex), (B=NaCl), (Z1=Zoledronic
acid monohydrate), (Z3=Zoledronic acid trihydrate).
[0017] FIG. 2 is an FTIR spectrum of a complex comprising
zoledronic acid, sodium zoledronic salt, and water.
[0018] FIG. 3 shows PXRD diffractograms of: (C=ammonium zoledronic
salt and water complex), (Z1=Zoledronic acid monohydrate), and
(Z3=Zoledronic acid trihydrate).
[0019] FIG. 4 is an FTIR spectrum of ammonium zoledronic salt and
water complex.
[0020] FIG. 5 shows PXRD diffractograms of: (D=zoledronic,
L-lysine, and water complex), (E=L-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0021] FIG. 6 is an FTIR spectrum of zoledronic, L-lysine, and
water complex.
[0022] FIG. 7 shows PXRD diffractograms of: (F=zoledronic,
DL-lysine, and water complex), (G=DL-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0023] FIG. 8 is an FTIR spectrum of zoledronic, DL-lysine, and
water complex.
[0024] FIG. 9 shows PXRD diffractograms of: (H=zoledronic acid,
zoledronic, DL-lysine, ethanol, and water complex), (G=DL-lysine),
(Z1=Zoledronic acid monohydrate), (Z3=Zoledronic acid
trihydrate).
[0025] FIG. 10 is an FTIR spectrum of zoledronic acid, zoledronic,
DL-lysine, ethanol, and water complex.
[0026] FIG. 11 shows PXRD diffractograms of: (I=zoledronic,
nicotinamide, and water complex), (J=nicotinamide), (Z1=Zoledronic
acid monohydrate), and (Z3=Zoledronic acid trihydrate).
[0027] FIG. 12 is an FTIR spectrum of zoledronic, nicotinamide, and
water complex.
[0028] FIG. 13 shows PXRD diffractograms of: (K=zoledronic,
adenine, and water complex), (L=adenine), (Z1=Zoledronic acid
monohydrate), (Z3=Zoledronic acid trihydrate).
[0029] FIG. 14 is an FTIR spectrum of zoledronic, adenine, and
water complex.
[0030] FIG. 15 shows PXRD diffractograms of: (M=zoledronic and
glycine complex), (N=glycine), (Z1=Zoledronic acid monohydrate),
and (Z3=Zoledronic acid trihydrate).
[0031] FIG. 16 is an FTIR spectrum of zoledronic and glycine
complex.
[0032] FIG. 17 shows PXRD diffractograms of: (O=zoledronic
diammonia water complex), (Z1=Zoledronic acid monohydrate), and
(Z3=Zoledronic acid trihydrate).
[0033] FIG. 18 is an FTIR spectrum of zoledronic diammonia water
complex.
[0034] FIG. 19 shows PXRD diffractograms of: (P=zoledronic,
DL-lysine, and water complex), (G=DL-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0035] FIG. 20 is an FTIR spectrum of zoledronic, DL-lysine, and
water complex.
[0036] FIG. 21 shows PXRD diffractograms of: (R=zoledronic,
DL-lysine, and water complex), (G=DL-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0037] FIG. 22 is an FTIR spectrum of zoledronic, DL-lysine, and
water complex.
[0038] FIG. 23 shows PXRD diffractograms of: (R=zoledronic,
DL-lysine, and water complex), (G=DL-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0039] FIG. 24 is an FTIR spectrum of zoledronic, DL-lysine, and
water complex.
[0040] FIG. 25 shows PXRD diffractograms of: (Q=zoledronic,
L-lysine, and water complex), (E=L-lysine), (Z1=Zoledronic acid
monohydrate), and (Z3=Zoledronic acid trihydrate).
[0041] FIG. 26 is an FTIR spectrum of zoledronic, L-lysine, and
water complex.
[0042] FIG. 27 shows the 24 hr rat plasma PK profile of parent
zoledronic acid and zoledronic acid complexes delivered via IV,
oral, and intraduodenal (ID) routes.
[0043] FIG. 28 shows the 4 hr rat plasma PK profile of parent
zoledronic acid and zoledronic acid complexes delivered orally.
[0044] FIG. 29 shows the 4 hr rat plasma PK profile of parent
zoledronic acid and zoledronic acid complexes delivered ID.
[0045] FIG. 30 shows the 24 hr rat plasma PK profile of parent
zoledronic acid and zoledronic acid complexes delivered by oral
gavage.
[0046] FIG. 31 shows the 4 hr rat plasma PK profile of parent
zoledronic acid and zoledronic acid complexes delivered orally.
[0047] FIG. 32 shows the 4 hr rat plasma PK profile of parent
zoledronic acid and selected zoledronic acid complexes delivered
orally.
[0048] FIG. 33 shows the dog serum PK profile of parent zoledronic
acid and zoledronic acid complexes delivered IV and orally.
[0049] FIG. 34 shows the 4 hr dog serum PK profile of parent
zoledronic acid and zoledronic acid complexes delivered IV and
orally.
[0050] FIG. 35 shows the dog serum PK profile of parent zoledronic
acid and zoledronic acid complexes delivered IV and orally; enteric
and non-enteric coated capsules.
[0051] FIG. 36 shows the 6 hr dog serum PK profile of parent
zoledronic acid and zoledronic acid complexes delivered IV and
orally; enteric and non-enteric coated capsules.
[0052] FIG. 37 shows the dog PK data for the enteric and
non-enteric coated hard gelatin capsules.
[0053] FIG. 38 shows the 24 hr dog serum PK profile of zoledronic
acid complexes delivered IV and orally.
[0054] FIG. 39 shows the 4 hr dog serum PK profile of zoledronic
acid complexes delivered IV and orally.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0055] In general, active pharmaceutical ingredients (APIs) in the
pharmaceutical compositions can be prepared in a variety of
different forms including prodrugs, amorphous forms, solvates,
hydrates, cocrystals, salts and polymorphs. The discovery of novel
API forms may provide an opportunity to improve the performance
characteristics of a pharmaceutical product. Additionally,
discovery of drug forms expands the array of resources available
for designing pharmaceutical dosage forms with targeted release
profiles or other desired characteristics.
[0056] A specific characteristic that can be targeted includes the
crystal form of an API. The alteration of the crystal form of a
given API would result in the modification of the physical
properties of the target molecule. For example, various polymorphs
of a given API exhibit different aqueous solubility, while the
thermodynamically stable polymorph would exhibit a lower solubility
than the meta-stable polymorph. In addition, pharmaceutical
polymorphs can also differ in properties such as rate of
dissolution, shelf life, bioavailability, morphology, vapor
pressure, density, color, and compressibility. Accordingly, it is
desirable to enhance the properties of an API by forming molecular
complexes such as a cocrystal, a salt, a solvate or hydrate with
respect to aqueous solubility, rate of dissolution,
bioavailability, Cmax, Tmax, physicochemical stability, down-stream
processability (e.g. flowability compressibility, degree of
brittleness, particle size manipulation), decrease in polymorphic
form diversity, toxicity, taste, production costs, and
manufacturing methods.
[0057] In the development of orally delivered drugs, it is often
advantageous to have novel crystal forms of such drugs that possess
improved properties, including increased aqueous solubility and
stability. In many cases, the dissolution rate increase of drugs is
desired as it would potentially increase their bioavailability.
This also applies to the development of novel forms of zoledronic
acid which, when administered orally to a subject could achieve a
greater or similar bioavailability and PK profile when compared to
an IV or other formulations on a dose-for-dose basis.
[0058] Cocrystals, salts, solvates and hydrates of zoledronic acid
of the present invention could give rise to improved properties of
zoledronic acid. For example, a new form of zoledronic acid is
particularly advantageous if it can improve the bioavailability of
orally delivered zoledronic acid. A number of novel zoledronic acid
forms have been synthesized, characterized, and disclosed herein.
Of particular interest are the zoledronic acid and the standard
amino acids since they have indicated enhanced permeability
compared with other molecular complexes of zoledronic acid. The
mechanism of enhanced permeability of these complexes is not yet
understood and, while not to be bound by this explanation, it is
possible that they moderate the formation of the insoluble
Ca.sup.2+ zoledronate salt resulting in more zoledronic acid to be
absorbed paracellularly through the tight junctions. It must be
stressed that this is a possible mechanism of enhanced
permeability.
[0059] Schematic diagrams for zoledronic acid:amino acid complexes
(a zoledronic acid:lysine complex and a zoledronic acid:glycine
complex, two embodiments of the invention) are shown below. The
diagrams show a molecular structure of the complex and possible
interactions between the constituents of the complex which is
different from the physical mix of the constituents.
[0060] 1. Zoledronic acid:lysine complex
##STR00002##
[0061] 2. Zoledronic acid:glycine complex
##STR00003##
These represent one of the arrangements that molecules of the drug
and the standard amino acids coformers could interact to form a
stable complex that even when stressed thermally at elevated
relative humidity (RH) environment have not displayed any signs of
deterioration or disintegration to its original constituents. Such
stability can be attributed to the hydrogen bonding (dashed line in
the box) in these molecular complexes. When packing in a crystal
structure these complexes have very different morphologies to that
of its constituents or their physical mix as indicated by their
powder X-ray diffraction (PXRD) patterns and therefore would
possess different, unpredictable physicochemical properties.
[0062] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic acid, sodium zoledronate
and water complex, characterized by an X-ray powder diffraction
pattern having strong peaks at about 8.1, 13.3, 21.5, 24.6, and
25.6.+-.0.2 degrees two-theta.
[0063] The present invention provides a new crystal form of
zoledronic acid in the form of ammonium zoledronic salt and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 11.0, 14.6, 15.4, 19.9, and
29.4.+-.0.2 degrees two-theta.
[0064] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic, L-lysine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 9.0, 14.4, 18.1, 26.0, and 29.6.+-.0.2
degrees two-theta.
[0065] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic, DL-lysine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 9.1, 14.7, 18.0, 21.2, and 26.0.+-.0.2
degrees two-theta.
[0066] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic acid, zoledronic,
DL-lysine, ethanol, and water complex, characterized by an X-ray
powder diffraction pattern having strong peaks at about 8.8, 9.7,
17.6, 23.1, and 26.5.+-.0.2 degrees two-theta.
[0067] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic acid, nicotinamide, and
water complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 13.1, 15.2, 21.0, 23.9, and
26.5.+-.0.2 degrees two-theta.
[0068] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic, adenine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 13.6, 15.9, 19.7, 27.9, and
29.5.+-.0.2 degrees two-theta.
[0069] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic and glycine complex,
characterized by an X-ray powder diffraction pattern having strong
peaks at about 10.2, 17.8, 19.9, 22.9, and 28.1.+-.0.2 degrees
two-theta.
[0070] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic diammonia water complex,
characterized by an X-ray powder diffraction pattern having strong
peaks at about 12.2, 13.0, 14.1, 17.1, and 19.3.+-.0.2 degrees
two-theta.
[0071] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic, DL-lysine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 8.3, 11.8, 12.3, 15.8, and 20.8.+-.0.2
degrees two-theta.
[0072] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic acid, L-lysine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 9.6, 10.7, 14.3, 21.4, 23.5.+-.0.2
degrees two-theta.
[0073] The present invention provides a new crystal form of
zoledronic acid in the form of zoledronic, DL-lysine, and water
complex, characterized by an X-ray powder diffraction pattern
having strong peaks at about 9.7, 10.8, 14.4, 18.9, 21.4.+-.0.2
degrees two-theta.
[0074] The present invention provides rat plasma or dog serum
concentration levels and PK profiles of IV, orally and ID delivered
zoledronic acid parent compound versus complexes of zoledronic acid
created using the method of this invention.
[0075] Accordingly, in a first aspect, the present invention
includes complexes of zoledronic acid with sodium, ammonium,
ammonia, L-lysine, DL-lysine, nicotinamide, adenine and glycine
which are capable of complexing in the solid-state, for example,
through dry or solvent-drop grinding (liquid assisted grinding),
heating or solvent evaporation of their solution in single or mixed
solvent systems, slurry suspension, supercritical fluids or other
techniques known to a person skilled in the art.
[0076] Another aspect of the invention provides zoledronic and
nicotinamide complex by dissolving both compounds in
water:ethylacetate (1:1 v/v) and allowing the solvent mixtures to
evaporate to form crystalline material.
[0077] Another aspect of the invention provides zoledronic and
glycine solid complex from dissolving both compounds in water, and
allowing the solvent to evaporate to form crystalline material.
[0078] Another aspect of the invention provides complexes of
zoledronic acid and sodium, ammonium, ammonia, L-lysine, DL-lysine,
nicotinamide, adenine and glycine suitable for a pharmaceutical
formulation than can be delivered orally to the human body. The
pharmaceutical formulation contains a therapeutically effective
amount of at least one of the novel molecular complexes of
zoledronic acid according to the invention and at least one
pharmaceutically acceptable carrier, (also known in the art as a
pharmaceutically acceptable excipient). The novel molecular
complexes of zoledronic acid are therapeutically useful for the
treatment and/or prevention of disease states associated with
osteoporosis, hypercalcemia (TIH), cancer induced bone metastasis,
Paget's disease or adjuvant or neoadjuvant therapies, discussed
above.
[0079] The invention also relates to methods of treatment using
novel molecular complexes of zoledronic acid of the invention or a
pharmaceutical formulation containing them. A pharmaceutical
formulation of the invention may be in any pharmaceutical form
which contains a novel molecular complex of zoledronic acid
according to the invention. The pharmaceutical formulation may be,
for example, a tablet, capsule, liquid suspension, injectable,
suppository, topical, or transdermal. The pharmaceutical
formulations generally contain about 1% to about 99% by weight of
at least one novel molecular complex of zoledronic acid of the
invention and 99% to 1% by weight of a suitable pharmaceutical
excipient.
[0080] Complexes of zoledronic acid and sodium, ammonium, ammonia,
L-lysine, DL-lysine, nicotinamide, adenine, and glycine have been
observed by their PXRD patterns and FTIR spectra.
[0081] Another aspect of the invention provides in-vivo data in
rats concerning the oral bioavailability of zoledronic acid
delivered orally and intraduodenally.
[0082] Another aspect of the invention provides PK profiles of the
parent compound delivered by different routes; IV, oral and ID.
[0083] Another aspect of the invention provides modified oral
bioavailability values of novel zoledronic acid complexes prepared
by the method of invention, compared with the orally delivered
parent compound.
[0084] Another aspect of the invention provides the addition of
excess at least one coformer to the zoledronic acid complexes,
which may be the same as the coformer in the complex, a different
coformer, or a mixture thereof.
[0085] Another aspect of the invention provides a method where the
excess cocrystal formers consist of standard amino acids.
[0086] Another aspect of the invention provides modified PK
profiles of zoledronic acid complexes with excess cocrystal
formers, compared with that of the orally delivered parent
compound.
[0087] Another aspect of the invention provides improved aqueous
solubility of novel zoledronic acid complexes compared with the
parent compound.
[0088] Another aspect of the invention provides modified oral
bioavailability values of novel zoledronic acid complexes with
excess cocrystal formers, compared with the orally delivered parent
compound.
[0089] Another aspect of the invention provides in vivo data in
dogs concerning the oral bioavailability of zoledronic acid
delivered IV or orally.
[0090] Another aspect of the invention provides modified oral
bioavailability values in dogs of novel zoledronic acid complexes
prepared by the method of invention delivered in gelatin capsules
compared with the orally delivered parent compound.
[0091] Another aspect of the invention provides modified oral
bioavailability values in dogs of novel zoledronic acid complexes
prepared by the method of invention delivered in enteric coated gel
capsules compared with that of the parent compound.
[0092] Another aspect of the invention provides substantial
improvement in oral bioavailability values in dogs of novel
zoledronic acid complexes with excess cocrystal formers prepared by
the method of invention delivered in hard gelatin capsules.
[0093] Another aspect of the invention provides slight improvement
in oral bioavailability values for zoledronic acid in dogs via
zoledronic acid and novel zoledronic acid complexes orally
delivered through enteric coated capsules.
[0094] Another aspect of the invention provides a reduced oral
bioavailability values for zoledronic acid in dogs via novel
zoledronic acid complexes with excess physical mix of coformer.
[0095] Another aspect of the invention provides a molecular complex
comprising a bisphosphonic acid or salt thereof and at least one
coformer, wherein the bioavailability of the bisphosphonic acid or
salt thereof from the molecular complex is greater than the
bioavailability of the bisphosphonic acid or salt thereof without
the coformer. The bisphosphonic acid may be, for example,
zoledronic acid, clodronic acid, tiludronic acid, pamidronic acid,
alendronic acid, residronic acid ibandronic acid or other
bisphosphonic acids known in the art.
[0096] Another aspect of the invention provides a method for
enhancing the bioavailabilty or permeability of a bisphosphonic
acid comprising the step of administering to a patient in need
thereof a therapeutically effective of a bisphosphonic acid in the
form of a molecular complex.
[0097] The techniques and approaches set forth in the present
disclosure can further be used by the person of ordinary skill in
the art to prepare variants thereof, said variants are considered
to be part of the inventive disclosure.
EXAMPLES
[0098] The following examples illustrate the invention without
intending to limit the scope of the invention.
[0099] Zoledronic acid as a starting material used in all
experiments in this disclosure was supplied by Farmkemi Limited
(Wuhan Pharma Chemical Co.), China with purity of ca. 98% and was
purified further via recrystallization from water. All other pure
chemicals (Analytical Grade) were supplied by Sigma-Aldrich and
used without further purification.
[0100] Enteric coating of gelatin capsules was contracted out to
AzoPharma, Hollywood, Fla., USA. A 10% w/w coating solution of
Eudragit L100-55, and triethyl citrate, 9.09 and 0.91 w/w %
respectively, in purified water and acetone was used in the Vector
LDCS pan coater to achieve a uniform coating layer on the capsules.
The coating uniformity and functionality for duodenal delivery was
tested by 2 hr dissolution in simulated gastric fluid stirred at 75
rpm and 37.degree. C. All capsules remained closed for the duration
of this test.
Solid Phase Characterization
[0101] Analytical techniques used to observe the crystalline forms
include powder X-ray diffraction (PXRD) and Fourier transform
infrared spectroscopy (FTIR). The particular methodology used in
such analytical techniques should be viewed as illustrative, and
not limiting in the context of data collection. For example, the
particular instrumentation used to collect data may vary; routine
operator error or calibration standards may vary; sample
preparation method may vary (for example, the use of the KBr disk
or Nujol mull technique for FTIR analysis).
[0102] Fourier Transform FTIR Spectroscopy (FTIR): FTIR analysis
was performed on a Perkin Elmer Spectrum 100 FTIR spectrometer
equipped with a solid-state ATR accessory.
[0103] Powder X-Ray Diffraction (PXRD): All zoledronic acid
molecular complex products were observed by a D-8 Bruker X-ray
Powder Diffractometer using Cu K.alpha. (.lamda.=1.540562 .ANG.),
40 kV, 40 mA. The data were collected over an angular range of
3.degree. to 40.degree. 2.theta. in continuous scan mode at room
temperature using a step size of 0.05.degree. 2.theta. and a scan
speed of 6.17.degree./min.
Example 1
Preparation of Zoledronic Acid, Sodium Zoledronic Salt, and Water
Complex
[0104] 200 mg of zoledronic acid was slurried with 180 mg of sodium
chloride in 1 mL of 1:1 ethanol:water overnight. The material was
filtered and rinsed. The particulate material was gathered and
stored in a screw cap vial for subsequent analysis. The material
was characterized by PXRD and FTIR corresponding to FIG. 1 and FIG.
2, respectively.
Example 2
Preparation of Ammonium Zoledronic Salt and Water Complex
[0105] 300 mg of zoledronic acid was slurried in 7N ammonia in
methanol overnight. The material was filtered and rinsed. The
particulate material was dissolved in water and left to evaporate
at ambient conditions to obtain colorless plates after 1 week. The
material was characterized by PXRD and FTIR corresponding to FIG. 3
and FIG. 4, respectively.
Example 3
Preparation of Zoledronic, L-Lysine, and Water Complex
[0106] 200 mg of zoledronic acid and 54 mg of L-lysine were
slurried in 2 mL of tetrahydrofuran and 200 .mu.l of water
overnight. The solids gathered after filtration were dried and
stored in a screw cap vials for subsequent analysis. The material
was characterized by PXRD and FTIR corresponding to FIG. 5 and FIG.
6, respectively.
Example 4
Preparation of Zoledronic, DL-Lysine, and Water Complex
[0107] 204 mg of zoledronic acid and 59 mg of DL-lysine were
slurried in 2 mL of tetrahydrofuran and 200 .mu.l of water
overnight. The solids gathered after filtration were dried and
stored in a screw cap vials for subsequent analysis. The material
was characterized by PXRD and FTIR corresponding to FIG. 7 and FIG.
8 respectively.
Example 5
Preparation of Zoledronic Acid, Zoledronic, DL-Lysine, Ethanol, and
Water
[0108] complex.
[0109] 103 mg of zoledronic acid and 54 mg of DL-lysine were
dissolved in 400 .mu.l of water, capped and stirred overnight. The
next day 0.25 mL of ethanol was added drop wise. The vial was
capped with a screw cap vial and after 1 day crystals appeared and
were filtered off. The material was stored for subsequent analysis.
The material was characterized by PXRD and FTIR corresponding to
FIG. 9 and FIG. 10 respectively.
Example 6
Preparation of zoledronic, nicotinamide, and water complex by
solvent-Drop Grinding
[0110] 99 mg of zoledronic acid was ground with 44 mg of
nicotinamide and 40 .mu.l of water was added to the solid mixture.
The solids gathered after grinding were stored in screw cap vials
for subsequent analysis. The material was characterized by PXRD and
FTIR corresponding to FIG. 11 and FIG. 12, respectively.
Example 7
Preparation of Zoledronic, Nicotinamide, and Water Complex from
Solution Crystallization
[0111] 25 mg of zoledronic acid and 138 mg of nicotinamide were
dissolved in 2 mL of a water:ethylacetate mix (1:1 v/v). The
solution was then allowed to stand for several hours to effect the
slow evaporation of solvent. The solids gathered were characterized
and produced very similar PXRD and FTIR patterns to that of Example
7 product.
Example 8
Preparation of Zoledronic, Adenine, and Water Complex by
Solvent-Drop Grinding
[0112] 96 mg of zoledronic acid was ground with 65 mg of adenine
and 60 .mu.L of water was added to the solid mixture. The solids
gathered after grinding were stored in screw cap vials for
subsequent analysis. The material was characterized by PXRD and
FTIR corresponding to FIG. 13 and FIG. 14, respectively.
Example 9
Preparation of Zoledronic, Adenine, and Water Complex from Solution
Slurry
[0113] 99 mg of zoledronic acid and 54 mg of adenine were slurried
in 2 mL of a water:ethanol mix (1:1 v/v) overnight. The solids
gathered after filtration were dried, characterized and produced
very similar PXRD and FTIR patterns to that of Example 8
product.
Example 10
Preparation of Zoledronic and Glycine Complex
[0114] 178 mg of zoledronic acid and 45 mg of glycine were slurried
in 2 mL of water overnight. The solids gathered after filtration
were dried and stored in a screw cap vials for subsequent analysis.
The material was characterized by PXRD and FTIR corresponding to
FIG. 15 and FIG. 16, respectively.
Example 11
Preparation of Zoledronic Diammonia Water Complex
[0115] 1.5 g of zoledronic acid was slurried in 7N ammonia in
methanol overnight. The material was filtered and rinsed. The
particulate material was dissolved in water with medium heat and
left to evaporate at ambient conditions to obtain colorless blocks
after 1 day. The material was characterized by PXRD and FTIR
corresponding to FIG. 17 and FIG. 18, respectively.
Example 12
Preparation of Zoledronic, DL-Lysine, and Water Complex
[0116] 200 mg of zoledronic acid and 102 mg of DL-lysine were
slurried in 2 mL of tetrahydrofuran and 400 .mu.l of water
overnight. The solids gathered after filtration were dried and
stored in a screw cap vials for subsequent analysis. The material
was characterized by PXRD and FTIR corresponding to FIG. 19 and
FIG. 20 respectively.
Example 13
Preparation of Zoledronic, DL-Lysine, and Water Complex
[0117] 1 g of zoledronic acid and 283 mg of DL-lysine were slurried
in 80 mL of tetrahydrofuran and 8 mL of water overnight. The solids
gathered after filtration were dried and stored in a screw cap
vials for subsequent analysis. The material was characterized by
PXRD and FTIR corresponding to FIG. 21 and FIG. 22
respectively.
Example 14
Preparation of Zoledronic, DL-Lysine, and Water Complex by
Antisolvent Method
[0118] This complex can also be prepared by the antisolvent method
by dissolving 1 g of zoledronic acid and 283 mg of DL-lysine in 5
mL of hot water and adding 40 mL of ethanol as an antisolvent
stirred overnight. Similar PXRD and FTIR profiles were obtained as
shown in FIGS. 23 and 24 respectively.
Example 15
Preparation of Zoledronic, L-Lysine, and Water Complex
[0119] 1 g of zoledronic acid and 255 mg of L-lysine were dissolved
in 60 mL of hot water. 100 mL of ethanol was then added as an
antisolvent. The solids gathered after filtration were dried and
stored in a screw cap vials for subsequent analysis. The material
was characterized by PXRD and FTIR corresponding to FIG. 25 and
FIG. 26 respectively.
Example 16
The Animal PK Studies
[0120] These studies were conducted on rats and dogs as they are
suitable animal models for zoledronic acid. This can be attributed
to the fact that both animals have historically been used in the
safety evaluation and PK screening studies and are recommended by
appropriate regulatory agencies. In addition, rats and dogs have
also been established as appropriate species for assessing the
absorption of bisphosphonate drugs including zoledronic acid.
[0121] Pure zoledronic acid and zoledronic acid complexes prepared
by the methods in this invention were delivered to the rats and
dogs through IV or oral routes. Additional tests included ID
administration in rats and administration of enteric coated
capsules in dogs. All compounds delivered were well tolerated by
the animals with no adverse events or physical abnormalities
noticed.
[0122] Test Subjects: 8-week male Sprague-Dawley Rats (217-259
grams) were obtained from Hilltop Lab Animals, Scottdale, Pa. USA.
Surgical catheters (jugular vein and intraduodenum) were implanted
to the animals prior to the study. Beagle dogs from Marshall Farms,
NY, USA, weighing from (9-12 kg) were used in this study. Surgical
catheters (jugular vein) were implanted prior to the study.
[0123] Housing: Rats were individually housed in stainless steel
cages to prevent catheter exteriorization. Acclimation (Pre-dose
Phase) was for 1 day. Dogs were already in the test facility
(Absorption Systems Inc., USA) and did not need acclimation.
[0124] Environment: Environmental controls for the animal room were
set to maintain 18 to 26.degree. C., a relative humidity of 30 to
70%, a minimum of 10 air changes/hour, and a 12-hour light/12-hour
dark cycle. The light/dark cycle could be interrupted for
study-related activities.
[0125] Diet: For rats, water and certified Rodent Diet #8728C
(Harlan Teklad) were provided. For dogs, water and the standard dog
chow diet were given twice daily (every 12 hours).
[0126] Fasting: All test animals were fasted overnight before IV,
oral, or ID administration of zoledronic acid or zoledronic acid
complexes.
[0127] Routes of Rat Dosing: Zoledronic acid and its complex
formulations were administered through IV, oral and ID. The doses
administered to all study rats were measured as zoledronic acid,
not as the complex form contained in the suspension: [0128] i. IV
Administration: the dose of zoledronic acid for IV administration
was 0.5 mg/kg. The dose of each rat was calculated on a per rat
basis (not on an average weight of all the rats in the lot). [0129]
ii. Oral gavage administration: solid suspensions were
administered. The dose of each rat was calculated on a per rat
basis (not on an average weight of all the rats in the lot). For
solid suspensions, animals were administered 5 mg/kg of zoledronic
acid or 5 mg/kg of zoledronic acid in zoledronic acid complexes
contained in a suspension of PEG 400. [0130] iii. Duodenal cannula
administration: solid suspensions were administered. The dose of
each rat was calculated on a per rat basis (not on an average
weight of all the rats in the lot). For solid suspensions, animals
were administered 5 mg/kg of zoledronic acid or 5 mg/kg of
zoledronic acid in zoledronic acid complexes contained in a
suspension of PEG 400.
[0131] Routes of Dog Dosing: Zoledronic acid and its complex
formulations were administered IV and orally. The doses
administered to all study dogs were measured as zoledronic acid in
each complex, not as the complex form contained in the powder in
the gelatin capsule or in solution for IV: [0132] i. IV
Administration: The dose volume of each dog was adjusted based upon
the average weight of the dog. [0133] ii. Oral administration:
zoledronic acid and its equivalent of zoledronic acid complex
formulations were administered through size 0 gelatin capsules
based on the average weight of the dogs. [0134] iii. Oral
administration with enteric coated capsules: zoledronic acid and
its equivalent of zoledronic acid complex formulations were
administered through size 0 enteric coated gelatin capsules based
on the average weight of the dogs. [0135] iv. Oral administration
of the molecular complexes with additional coformers: physical
mixtures of zoledronic acid complexes with additional coformers
were administered through size 0 gelatin capsules based on the
average weight of the dogs.
[0136] Groups: Two major groups of animals were selected for the
study. [0137] Group 1, rats that contained four subgroups (I-IV)
where the results of each data point on the PK profile graphs was
the average drug concentration in the plasma of 3 rats. [0138]
Group 2, dog PK study contained three groups with subgroups (A, B,
C, D, E and F) where the results of each data point on the PK
profile graphs was the average drug concentration in the serum of 5
dogs.
[0139] Details of Group 1 Rat Dosing
[0140] Group I (IV administration). Group members, designated IV
doses are listed below
TABLE-US-00001 Group # of Dose # I Designation rats Dose* volume G1
Zoledronic 3 0.5 mg/kg 1 mL Acid
IV comparator group, was conducted to calculate MAT (mean
absorption time) and ka (absorption rate constant) for the oral
groups.
[0141] Group II (oral gavage): Group designations and oral doses
are listed below:
TABLE-US-00002 Dose Group # of volume # II Designation Rats Dose*
mL/kg Compound G2 Zoledronic 3 5 mg/kg 1 mL Zoledronic acid Acid in
PEG400 G3 Solid 3 5 mg/kg 1 mL Zoledronic and suspension equivalent
glycine complex in PEG400 G4 Solid 3 5 mg/kg 1 mL Zoledronic,
suspension equivalent nicotinamide, in PEG400 and water complex G5
Solid 3 5 mg/kg 1 mL Zoledronic acid, suspension equivalent sodium
zoledronic in PEG400 salt, and water complex G6 Solid 3 5 mg/kg 1
mL Zoledronic, L- suspension equivalent lysine, and water in PEG400
complex G7 Solid 3 5 mg/kg 1 mL Zoledronic, DL- suspension
equivalent lysine, and water in PEG400 complex
[0142] Group III (ID administration): Group designations and oral
doses are listed below:
TABLE-US-00003 Dose Group # of volume # III Designation rats Dose*
mL/kg Compound G8 Zoledronic 3 5 mg/kg 1 mL Zoledronic acid Acid in
PEG400 G9 Solid 3 5 mg/kg 1 mL Zoledronic and suspension equivalent
glycine complex in PEG400 G10 Solid 3 5 mg/kg 1 mL Zoledronic,
suspension equivalent nicotinamide, and in PEG400 water complex G11
Solid 3 5 mg/kg 1 mL Zoledronic acid, suspension equivalent sodium
zoledronic in PEG400 salt, and water complex G12 Solid 3 5 mg/kg 1
mL Zoledronic, L- suspension equivalent lysine, and water in PEG400
complex G13 Solid 3 5 mg/kg 1 mL Zoledronic, DL- suspension
equivalent lysine, and water in PEG400 complex
[0143] Group IV (oral gavage): Group designations and oral doses
are listed below:
TABLE-US-00004 Excess coformer Group # of Dose Excess amount # IV
Compound rats Dose volume/kg coformer mg/kg G14 Zoledronic and 3 5
mg/kg 1 mL Glycine 45 glycine complex, equivalent solid suspension
in PEG400 G15 Zoledronic and 3 5 mg/kg 1 mL Glycine 25 glycine
complex, equivalent solid suspension in PEG400 G16 Zoledronic and 3
5 mg/kg 1 mL Glycine 5 glycine complex, equivalent solid suspension
in PEG400 G17 Zoledronic, DL- 3 5 mg/kg 1 mL DL-lysine 39.32
lysine, and water equivalent monohydrate complex, solid suspension
in PEG400 G18 Zoledronic, DL- 3 5 mg/kg 1 mL DL-lysine 28.08
lysine, and water equivalent monohydrate complex, solid suspension
in PEG400 G19 Zoledronic, DL- 3 5 mg/kg 1 mL DL-lysine 5.62 lysine,
and water equivalent monohydrate complex, solid suspension in
PEG400 G20 Zoledronic, DL- 3 5 mg/kg 1 mL n/a n/a lysine, and water
equivalent complex, solid suspension in PEG400
[0144] Rat blood sample collection, handling and analysis: Blood
(approx. 300 .mu.L per sample) samples were withdrawn from each of
3 animals in Group I (IV administration) at eight (8) time points:
5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hrs, after
initial administration of zoledronic acid or its complexes, into
EDTA plasma tubes. Plasma was collected after centrifugation at
13,000 rpm for 5 min at 4.degree. C. and immediately frozen and
stored at -60 to -80.degree. C. till analysis.
[0145] Samples were thawed on the day of analysis and the amount of
zoledronic acid in the samples was quantified by analyzed by
LC/MS/MS method.
[0146] Details of Group 2 dog dosing: Prior to dosing, all dogs
received a 20 mL dose of citric acid (24 mg/mL in water) to lower
the pH of their stomach. After dosing capsules or IV, all dogs
received additional 6.25 mL citric acid solution (24 mg/mL in
water) as a rinse.
[0147] Group A, (IV administration). Group members, designated IV
doses are listed below:
TABLE-US-00005 Group # of Dose # A Designation fasted Dogs Dose*
volume Leg 1 Zoledronic 5 0.05 mg/kg 1 mL/kg Acid
IV comparator group, was conducted to calculate MAT (mean
absorption time) and ka (absorption rate constant) for the oral
groups.
[0148] Group B (oral administration): Group designations and oral
doses are listed below:
TABLE-US-00006 Dose of Dosing compound in # of Solution Group
Dosing the gelatin fasted Dogs Conc. # B Compound Route capsules
(9-12 kg) mg/mL Leg 2 Zoledronic oral 5 mg/kg 5 n/a acid equivalent
Leg 3 Zoledronic oral 5 mg/kg 5 n/a and glycine equivalent complex
Leg 4 Zoledronic, oral 5 mg/kg 5 n/a DL-lysine, equivalent and
water complex Leg 5 Zoledronic, oral 5 mg/kg 5 n/a L-lysine,
equivalent and water complex Leg 6 Zoledronic, oral 5 mg/kg 5 n/a
DL-lysine, equivalent and water complex
[0149] Group C (oral administration): Group designations and oral
doses are listed below:
TABLE-US-00007 Dose of # of compound in Excess Group fasted Dosing
the gelatin Excess coformer # C Compound Dogs (9-12 kg) Route
capsules coformer amount Leg 7 Zoledronic acid 5 oral 56.0 mg;
enteric n/a n/a monohydrate coated capsules Leg 8 Zoledronic and 5
oral 67.0 mg; enteric n/a n/a glycine complex coated capsules Leg 9
Zoledronic, DL- 5 oral 87.7 mg DL-lysine 294.8 mg lysine, and
monohydrate wate complex Leg 10 Zoledronic, DL- 5 oral 87.7 mg;
enteric DL-lysine 294.8 mg lysine, and coated capsules monohydrate
water complex Leg 11 Zoledronic, DL- 5 oral 84.2 mg DL-lysine 294.8
mg lysine, and monohydrate water complex Leg 12 Zoledronic, DL- 5
oral 87.7 mg; enteric n/a n/a lysine, and coated capsules water
complex
[0150] Group D, (15 min IV infusion): Group members, designated IV
doses are listed below:
TABLE-US-00008 # of Dosing Group fasted Dogs solution # D
Designation (9-12 kg) Dose* concentration Leg 13 Zoledronic 5 0.183
mg/kg 0.1 mg/mL Acid IV
[0151] Group E, (oral administration): Group members, designated IV
doses are listed below:
TABLE-US-00009 # of Dose of compound Excess Group fasted Dosing in
the gelatin Excess coformer # E Compound Dogs (9-12 kg) Route
capsules coformer amount Leg 14 Zoledronic, DL- 2.1 oral 35.4 mg
DL-lysine 123.8 mg lysine, and monohydrate water complex Leg 15
Zoledronic and 5 oral 67.0 mg DL-lysine 294.8 mg glycine complex
monohydrate Leg 16 Zoledronic, L- 5 oral 87.7 mg DL-lysine 294.8 mg
lysine, and monohydrate water complex Leg 17 Zoledronic, DL- 2.1
oral 35.4 mg DL-lysine 294.8 mg lysine, and monohydrate water
complex
[0152] Group F, (15 min IV infusion): Group members, designated IV
doses are listed below:
TABLE-US-00010 # of Dosing Group fasted Dogs solution # F
Designation (9-12 kg) Dose* concentration Leg 18 Zoledronic 5 0.12
mg/kg 0.1 mg/mL Acid IV infusion
[0153] After initial administration of zoledronic acid or its
complexes, blood (approx. 2.5 mL per sample) was withdrawn from
each of 5 animals in Group A (IV administration) at 15 time points:
Pre-dose (0), 2, 5, 10, 15, 30, 45 min, 1, 1.5, 2, 4, 6, 8, 24 and
48 hrs and at 13 time points for Group B (oral administration):
Pre-dose (0), 5, 10, 15, 30, 45 min, 1, 1.5, 2, 4, 6, 8, and 24
hrs. Blood samples were placed without the use of an anticoagulant
and allowed to sit at room temperature for approximately 30
minutes. Samples were then centrifuged at a temperature of
4.degree. C., at a speed of 13,000 rpm, for 5 minutes. Serum was
collected and split into two aliquots and stored frozen
(-80.degree. C.) till analysis. Samples were thawed on the day of
analysis and processed using analytical procedures for zoledronic
acid containing an LC/MS/MS analysis method.
[0154] Animal PK Studies Results
[0155] Rat study: The results of the first rat study are summarized
in Table 1; the concentrations (ng/mL) of zoledronic acid in the
plasma samples are the average values of the analytical results of
3 rats. In addition, the PK profiles of the IV, oral and ID groups
are shown in FIG. 27. The profiles of oral and ID groups are shown
in FIGS. 28 and 29. It suggests that some zoledronic acid complexes
have improved oral bioavailability compared with that of the parent
zoledronic acid. The complexes with improved bioavailability were
further tested in a second rat PK study in which excess coformers
were added to the zoledronic acid complexes and then administered
to rats by oral gavage. The results of this second study are
summarized in Table 2 and their PK profiles are shown in FIGS. 30,
31 and 32. These figures show improved bioavailabilities of several
zoledronic acid complexes with excess coformers.
[0156] Dog study: The results of the first dog study are summarized
in Table 3. The concentrations (ng/mL) of zoledronic acid are the
average values of the analytical results of 5 dogs. The PK profiles
of the IV and oral groups are shown in FIGS. 33 and 34 which
represent the first four hours of the 48 hr PK profile. These
results and FIG. 34 suggest that most if not all zoledronic acid
complexes have achieved improved oral bioavailability compared to
that of the parent zoledronic acid delivered orally.
[0157] The results of the second dog study are summarized in Table
4; the concentrations (ng/mL) of zoledronic acid shown are the
average values of the analytical results of 5 dogs. The PK profiles
of the IV and oral groups are shown in FIGS. 35 and 36. FIG. 36
represents the first 6 hours of the 24 hour PK profile. These
results and FIG. 35 suggest that most if not all zoledronic acid
complexes have achieved improved oral bioavailability compared with
that of the parent zoledronic acid delivered orally. Specifically,
there was a significant improvement in zoledronic acid
bioavailability for the novel zoledronic acid complexes with excess
amino acid coformer (Leg 11, FIG. 37) compared to that of the
parent drug. The results have also shown that there was improvement
in the bioavailability of the enterically coated capsules compared
with the non-enterically coated capsules (FIG. 37, Legs 7 and 2,
Legs 8 and 3, Legs 12 and 4), but surprisingly the bioavailability
was significantly altered when excess amino acid coformer was added
to form a physical mixture to the enterically coated capsules (FIG.
37, Legs 9 and 10). The reason behind it is not fully
understood.
[0158] The results have shown that there is a slight increase in
the oral bioavailability of zoledronic acid from the enteric coated
capsules filled with neat (i.e. with no excess coformer) zoledronic
acid amino acid complex. Therefore, it is expected that the excess
coformer with the novel zoledronic acid complexes would also lead
to increased bioavailability when delivered in enterically coated
capsules. Surprisingly, when excess coformer was added to the
zoledronic acid, the bioavailability of the enterically coated
capsules was lower than that of the non-enterically coated
capsules. This suggests that a physical powder mixture of the
molecular complex and excess coformer might decrease the
bioavailability when delivered to the duodenum.
[0159] The analytical results of the third dog study are shown in
Table 5, which contains averaged data from five dogs. The PK
profiles of the IV and oral groups are shown in FIGS. 38 and 39.
FIG. 39 represents the first 4 hours of the 24 hour PK profile.
TABLE-US-00011 TABLE 1 Rat plasma concentrations for pure
zoledronic acid and zoledronic acid complexes via different routes
of delivery. Average plasma con- centration Group Dosing Vehi- Time
of 3 Rats # Complex Route cle (hour) (ng/mL) G1 Zoledronic IV Water
0.083333 3254.05 acid 0.25 1950.62 0.5 1128.75 1 404.28 2 112.68 4
30.46 8 10.66 24 2.98 G2 Zoledronic PO PEG 0.25 330.06 acid 400 0.5
267.45 1 138.91 2 47.72 4 11.78 8 2.00 24 0.00 G3 Zoledronic PO PEG
0.25 648.01 and 400 0.5 435.38 glycine 1 200.88 complex 4 12.78 8
1.46 24 0.00 G4 Zoledronic, PO PEG 0.25 434.61 nicotinamide, 400
0.5 304.94 and water 1 122.35 complex 4 7.68 8 1.82 24 0.00 G5
Zoledronic PO PEG 0.25 278.47 acid, sodium 400 0.5 280.20
zoledronic 1 171.59 salt, and 4 13.42 water 8 1.78 complex 24 0.00
G6 Zoledronic, PO PEG 0.25 258.43 L-lysine, 400 0.5 249.82 and
water 1 184.95 complex 4 28.70 8 3.27 24 0.00 G7 Zoledronic, PO PEG
0.25 494.31 DL-lysine, 400 0.5 379.27 and water 1 213.48 complex 4
14.57 8 3.42 24 0.00 G8 Zoledronic ID PEG 0.25 145.67 acid 400 0.5
109.92 1 47.36 2 12.94 4 3.85 8 0.97 24 0.00 G9 Zoledronic ID PEG
0.25 86.51 and 400 1 33.93 glycine 4 1.75 complex 8 1.55 24 0.00
G10 Zoledronic, ID PEG 0.25 69.71 nicotinamide, 400 1 21.03 and
water 4 0.86 complex 8 0.00 24 0.00 G11 Zoledronic ID PEG 0.25
39.99 acid, sodium 400 1 18.50 zoledronic 4 0.71 salt, and 8 0.00
water 24 0.00 complex G12 Zoledronic, ID PEG 0.25 91.21 L-lysine,
400 1 26.53 and water 4 0.74 complex 8 0.00 24 0.00 G13 Zoledronic,
ID PEG 0.25 98.25 DL-lysine, 400 1 34.61 and water 4 2.65 complex 8
1.02 24 0.80
TABLE-US-00012 TABLE 2 Rat plasma concentrations for zoledronic
acid complexes with excess coformers, delivered by oral gavage
Average plasma con- centration Group Dosing Vehi- Time of 3 Rats #
Complex Route cle (hour) (ng/mL) G14 Zoledronic PO PEG 0.0333333
14.61 and glycine 400 0.0833333 206.26 complex and 0.1666667 340.19
45 mg/kg 0.25 375.99 glycine 0.5 321.36 1 197.01 4 17.35 24 0.00
G15 Zoledronic PO PEG 0.0333333 24.48 and glycine 400 0.0833333
281.08 complex and 0.1666667 502.20 25 mg/kg 0.25 516.58 glycine
0.5 430.10 1 203.48 2 73.27 4 14.70 24 0.00 G16 Zoledronic PO PEG
0.0333333 60.03 and glycine 400 0.0833333 365.23 complex and
0.1666667 563.83 5 mg/kg 0.25 625.05 glycine 0.5 464.34 1 209.65 2
74.28 4 12.17 24 0.00 G17 Zoledronic, PO PEG 0.0333333 168.19
DL-lysine, 400 0.0833333 263.28 and water 0.1666667 440.26 complex
and 0.25 456.18 39.32 mg/kg 0.5 385.57 DL-lysine 1 209.26
monohydrate 2 85.65 4 14.58 24 0.71 G18 Zoledronic, PO PEG
0.0333333 219.95 DL-lysine, 400 0.0833333 427.02 and water
0.1666667 729.65 complex and 0.25 777.54 28.08 mg/kg 0.5 632.07
DL-lysine 1 300.86 monohydrate 2 100.59 4 21.14 24 0.00 G19
Zoledronic, PO PEG 0.0333333 53.78 DL-lysine, 400 0.0833333 394.73
and water 0.1666667 649.52 complex and 0.25 669.20 5.62 mg/kg 0.5
530.00 DL-lysine 1 265.20 monohydrate 2 73.31 4 15.41 24 0.00 G20
Zoledronic, PO PEG 0.0333333 103.13 DL-lysine, 400 0.0833333 352.18
and water 0.1666667 475.33 complex 0.25 505.48 0.5 431.41 1 224.56
2 69.95 4 14.96 24 0.00
TABLE-US-00013 TABLE 3 Dog serum concentrations for pure zoledronic
acid and zoledronic acid complexes via different routes of delivery
(IV and oral). Average serum con- centration Leg Dosing Vehi- Time
of 5 dogs # Complex Route cle (hour) (ng/mL) 1 0.05 mg/kg IV Saline
0 0.00 Zoledronic solution 0.0333 413.44 acid 0.0833 311.68 0.1667
228.97 0.25 178.63 0.5 111.11 0.75 75.91 1 56.07 1.5 30.35 2 17.61
4 4.29 8 1.13 24 0.00 48 0.00 2 56.0 mg PO n/a 0 0.00 Zoledronic
acid 0.0833 0.00 monohydrate 0.1667 0.00 capsule 0.25 0.31 0.5
110.73 0.75 97.98 1 103.60 1.5 80.57 2 75.16 4 17.86 8 2.71 24 0.56
3 67.0 mg PO n/a 0 0.00 Zoledronic and 0.0833 2.45 glycine complex
0.1667 12.75 capsule 0.25 37.07 0.5 149.20 0.75 206.14 1 254.20 1.5
176.11 2 109.25 4 20.43 8 3.96 24 0.97 4 87.7 mg PO n/a 0 0.00
Zoledronic, 0.0833 3.11 DL-lysine, and 0.1667 6.49 water complex
0.25 22.55 capsule 0.5 68.28 0.75 162.72 1 206.14 1.5 149.92 2
105.81 4 25.51 8 4.22 24 0.56 5 87.7 mg PO n/a 0 0.00 Zoledronic,
0.0833 0.00 L-lysine, and 0.1667 3.13 water complex 0.25 10.06
capsule 0.5 188.52 0.75 345.28 1 318.97 1.5 180.77 2 109.23 4 23.11
8 9.73 24 1.93 6 84.2 mg PO n/a 0 0.00 Zoledronic, 0.0833 0.00
DL-lysine, and 0.1667 0.20 water complex 0.25 1.92 capsule 0.5
106.47 0.75 120.13 1 108.13 1.5 90.45 2 54.48 4 18.14 8 4.35 24
1.06
TABLE-US-00014 TABLE 4 Dog serum concentrations for pure zoledronic
acid and zoledronic acid complexes via different routes of delivery
IV and oral; enteric and non-enteric coated gelatin capsules.
Average serum con- centration Leg Dosing Vehi- Time of 5 dogs #
Complex Route cle (hour) (ng/mL) 7 56.0 mg PO n/a 0 0.00 Zoledronic
acid 0.1667 0.00 monohydrate 0.25 0.00 enteric coated 0.5 0.00
capsule 0.75 0.00 1 9.84 1.5 86.13 2 109.37 4 107.64 6 14.15 8 4.57
24 0.50 8 67.0 mg PO n/a 0 0.00 Zoledronic and 0.1667 0.00 glycine
complex 0.25 0.00 enteric coated 0.5 0.00 capsule 0.75 0.00 1 4.42
1.5 208.97 2 274.53 4 101.20 6 16.71 8 7.14 24 2.17 9 87.7 mg PO
n/a 0 0.00 Zoledronic, 0.0833 13.31 DL-lysine, and 0.1667 39.76
water complex 0.25 120.41 with 294.8 mg 0.5 364.68 DL-lysine 0.75
487.59 monohydrate 1 499.60 capsule 1.5 362.16 2 254.72 4 52.22 6
16.61 8 8.93 24 2.92 10 87.7 mg PO n/a 0 0.00 Zoledronic, 0.1667
0.00 DL-lysine, and 0.25 0.00 water complex 0.5 0.00 with 294.8 mg
0.75 3.71 DL-lysine 1 51.32 monohydrate 1.5 403.15 enteric coated 2
309.08 capsule 4 44.83 6 13.15 8 7.09 24 2.66 11 84.2 mg PO n/a 0
0.22 Zoledronic, 0.1667 167.03 DL-lysine, and 0.25 533.96 water
complex 0.5 878.63 with 294.8 mg 0.75 838.82 DL-lysine 1 633.50
monohydrate 1.5 326.63 capsule 2 185.44 4 46.86 6 20.26 8 11.49 24
5.95 12 87.7 mg PO n/a 0 0.57 Zoledronic, 0.1667 0.60 DL-lysine,
and 0.25 0.59 water complex 0.5 0.61 enteric coated 0.75 0.40
capsule 1 132.15 1.5 566.18 2 402.12 4 65.35 6 21.02 8 12.18 24
4.33 13 0.183 mg/kg IV Saline 0 0.64 Zoledronic solution 0.0833
476.79 acid 0.1667 755.68 0.25 1057.75 0.3333 745.67 0.4167 629.22
0.5 522.78 0.75 342.58 1 245.36 1.25 182.59 1.5 139.77 2 80.87 4
23.40 8 8.78 24 3.84
TABLE-US-00015 TABLE 5 Dog serum concentrations for pure zoledronic
acid and zoledronic acid complexes via different routes of delivery
(IV and oral). Average serum con- centration Leg Dosing Vehi- Time
of 5 dogs # Complex Route cle (hour) (ng/mL) 14 35.4 mg PO n/a 0
0.00 Zoledronic, 0.0833 0.00 DL-lysine, and 0.1667 0.72 water
complex, 0.25 11.40 with 123.8 mg 0.5 78.95 DL-lysine 0.75 126.46
monohydrate 1 137.38 gelatin capsule 1.5 64.73 2 33.38 4 6.14 8
0.89 24 0.00 15 67.0 mg PO n/a 0 0.00 Zoledronic and 0.0833 2.58
glycine complex, 0.1667 26.13 with 294.8 mg 0.25 55.58 DL-lysine
0.5 225.41 monohydrate 0.75 234.95 gelatin capsule 1 221.91 1.5
204.90 2 117.22 4 17.79 8 3.34 24 0.77 16 87.7 mg PO n/a 0 0.00
Zoledronic, 0.0833 3.26 L-lysine, and 0.1667 17.21 water complex,
0.25 213.77 with 294.8 mg 0.5 504.17 DL-lysine 0.75 436.00
monohydrate 1 325.21 gelatin capsule 1.5 171.42 2 100.81 4 23.38 8
4.65 24 1.48 17 35.4 mg PO n/a 0 0.00 Zoledronic, 0.0833 0.00
DL-lysine, and 0.1667 13.47 water complex, 0.25 50.04 with 294.8 mg
0.5 146.68 DL-lysine 0.75 137.24 monohydrate 1 116.38 gelatin
capsule 1.5 66.70 2 44.94 4 8.87 8 1.58 24 0.21 18 0.12 mg/kg IV
Saline 0 0.00 Zoledronic solution 0.0833 309.13 acid 0.1667 524.58
0.25 717.15 0.3333 501.70 0.4167 392.35 0.5 322.84 0.75 201.78 1
132.86 1.25 93.22 1.5 69.06 2 38.38 4 9.14 8 3.24 24 1.21
TABLE-US-00016 TABLE 6 Aqueous solubility of zoledronic acid (ZA)
and novel zoledronic acid complexes at room temperature. Conc.
mMol/L Compound mg/mL (complex) ZA monohydrate 1.57 5.41 ZA:
Glycine 11.89 34.25 ZA: L-Lysine dihydrate 8.22 18.09 ZA: DL-Lysine
dihydrate 6.85 15.08 ZA: DL-Lysine monohydrate 13.9 31.86
* * * * *